Why QR Codes Now on Vaccines & Antibiotics: Schedule H2, Spurious Drugs and AMR Explained

Expansion of the track-and-trace net: The MoHFW has amended the Drugs Rules, 1945 to bring all vaccines, antimicrobials, anti-cancer medicines, and narcotic and psychotropic drugs under Schedule H2, the schedule that mandates barcode/QR-code labelling. Until now this requirement applied only to a list of the top 300 drug brands; the amendment greatly widens coverage to entire therapeutic categories that are either high-value, high-risk, or critical to public health.

Where the code must go: Manufacturers must print or affix a barcode or QR code on the primary packaging label of the formulation. Where there is inadequate space (for example, on small blister strips or vials), the code may be placed on the secondary packaging label.

Phased compliance: To give the industry time to retool packaging lines, the rules prescribe staggered deadlines — vaccines, anti-cancer medicines and narcotic/psychotropic drugs from 1 July 2027, and antimicrobials from 1 July 2028.

Why these categories: Vaccines and anti-cancer drugs are high-value and life-critical, making them attractive targets for counterfeiting; narcotic and psychotropic drugs carry diversion and abuse risks; and antimicrobials are central to the AMR crisis. Tracking them end-to-end addresses both patient safety and a major public-health threat.

The parent law: Drug regulation in India rests on the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945. The Act provides the framework (definitions, standards, penalties) while the Rules contain the operational detail, including the schedules and labelling requirements. The QR-code mandate is an amendment to these Rules.

The central regulator (CDSCO): The Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services in the MoHFW, is India's national drug regulator. It is headed by the Drugs Controller General of India (DCGI), who approves new drugs, clinical trials and licences for certain critical categories.

Key advisory and testing bodies: The Drugs Technical Advisory Board (DTAB) is the highest statutory advisory body on technical matters (it recommended the QR-code framework); the Drugs Consultative Committee (DCC) advises on uniform administration; and the Central Drugs Laboratory (CDL), Kolkata is the apex statutory testing laboratory.

Centre–State division: Drug regulation is a shared responsibility. The Centre (CDSCO) handles approvals, imports and standards, while State Drug Controllers and Drug Inspectors license manufacturing/sale and enforce quality on the ground — a structure that has long been criticised for uneven enforcement across States.

Schedule H: This lists prescription-only drugs that cannot be sold over the counter without the prescription of a registered medical practitioner; most antibiotics fall here.

Schedule H1: Introduced in 2013–14 specifically to check the misuse of antibiotics and certain habit-forming drugs, it requires the chemist to maintain a separate register recording the prescriber, patient and drug for three years. It was a direct regulatory response to AMR.

Schedule X: This covers narcotic and psychotropic substances and other drugs with high abuse potential, subject to the strictest controls — special licences, double-locked storage and detailed record-keeping.

Schedule H2 (the present focus): Inserted in 2022, Schedule H2 is not about prescription control but about traceability — it lists formulations that must carry a barcode/QR code for authentication and tracking across the supply chain. The new amendment adds whole categories (vaccines, antimicrobials, anti-cancer, narcotic/psychotropic) to this schedule.

Track and trace, defined: A track-and-trace system assigns each pack a unique, machine-readable identity so its movement can be followed ("tracked") forward from the factory to the patient and traced back ("traced") to its origin if a problem arises. This enables authentication, recall of faulty batches, and detection of fakes.

What the code stores: The QR code (or barcode) typically encodes the unique product identification code, the generic and brand names, the name and address of the manufacturer, the batch number, the manufacturing and expiry dates, the manufacturing licence number, and details of excipients where applicable. Scanning the code with a software application allows verification at any point in the chain.

Origin of the framework: The mandate began with the Drugs (Eighth Amendment) Rules, 2022, which inserted Schedule H2 and required the top 300 brands to carry codes from 1 August 2023, on the recommendation of the DTAB.

Exports already covered: A large share of India's pharmaceutical exports already carries serialisation/traceability data to meet importing countries' requirements; the present reform extends comparable safeguards to medicines sold within India.

Not of Standard Quality (NSQ): Under the Drugs and Cosmetics Act, a drug that fails to meet the prescribed pharmacopoeial standards (for instance, in assay, dissolution, sterility or content) is declared NSQ. CDSCO publishes monthly NSQ alerts after testing market samples.

Spurious drugs: These are fake or falsely-labelled drugs that imitate or are passed off as another drug — the core problem the QR-code system targets. Manufacturing or selling spurious or adulterated drugs that cause death or grievous hurt attracts severe penalties, including imprisonment that may extend to life.

Adulterated and misbranded drugs: Adulterated drugs contain filthy, contaminated or harmful substances; misbranded drugs carry false, misleading or incomplete labelling. Each is separately defined and penalised under the Act.

Why traceability helps: A unique, verifiable code makes it far harder to introduce counterfeit packs into the legitimate supply chain and makes targeted recalls of substandard batches faster and more reliable.

What AMR is: Antimicrobial resistance (AMR) occurs when microbes (bacteria, viruses, fungi, parasites) evolve so that medicines such as antibiotics no longer work, making infections harder to treat. The WHO lists AMR among the top global health threats, and resistant organisms are popularly called "superbugs."

The India context: India is one of the world's largest consumers of antibiotics, and the resistance determinant New Delhi Metallo-beta-lactamase-1 (NDM-1) was first reported from this region. Drivers include over-the-counter sale of antibiotics, incorrect dosing, use of antibiotics as growth promoters in livestock and poultry, and pharmaceutical effluent discharge.

How traceability fits in: Substandard and counterfeit antimicrobials — containing too little active ingredient — expose microbes to sub-therapeutic doses, which actively breeds resistance. By enabling identification and removal of fake or low-quality antimicrobials, QR-code traceability complements India's broader AMR response.

The wider AMR toolkit: India's response includes Schedule H1 (to curb OTC antibiotic sale), the National Action Plan on AMR (2017), the ICMR-led Antimicrobial Resistance Surveillance Network (AMRSN), the "Red Line" campaign on antibiotic packaging, and the One Health approach linking human, animal and environmental health.

Compliance cost and small label space: Printing legible, unique codes on tiny blister strips and vials is technically demanding, and the recurring cost of serialisation can strain small and mid-size manufacturers.

Last-mile verification: The system's value depends on pharmacies, hospitals and patients actually scanning codes; without widespread verification at the point of sale, traceability data remains underused.

Enforcement gaps: India's split Centre–State regulatory structure produces uneven enforcement, and a QR code on the pack does not by itself guarantee the quality of the medicine inside — it must be backed by robust sampling and laboratory testing.

Coverage limits: The mandate, even after expansion, does not cover every medicine sold in India, leaving large parts of the market outside formal traceability for now.

Support smaller manufacturers: Provide technical and financial help so that compliance costs do not push small units out of the formal market.

Promote point-of-sale verification: Encourage pharmacists, hospitals and patients to scan codes through simple, widely available apps to realise the system's full value.

Strengthen testing and enforcement: Pair traceability with expanded laboratory capacity, more drug inspectors, and harmonised Centre–State enforcement.

Integrate with AMR strategy: Use traceability data alongside Schedule H1 enforcement, surveillance and the One Health approach for a coordinated response to resistant infections.